Header

UZH-Logo

Maintenance Infos

Potential future uses of calcimimetics in patients with chronic kidney disease


Chonchol, M; Wüthrich, R P (2008). Potential future uses of calcimimetics in patients with chronic kidney disease. NDT Plus, 1(Supple):i36-i41.

Abstract

Cinacalcet has proven effective in the treatment of
secondary hyperparathyroidism (SHPT) in dialysis
patients, and it may also have benefits in stage 3 and 4
chronic kidney disease (CKD). The efficacy of cinacalcet
in the treatment of SHPT was investigated in a study of
54 patients with stage 3 and 4 CKD not receiving dialysis.
A significant number of these patients achieved at least a
30% reduction in parathyroid hormone (PTH) from baseline
with cinacalcet therapy compared with placebo (56%
versus 19%; P=0.006).Another potential use of cinacalcet
is in the treatment of persistent hyperparathyroidism (HPT)
after kidney transplantation. The pathophysiologic considerations for persistent HPT in patients who have undergone renal transplantation are different from those in stage 3 and 4 CKD. Post-transplant patients with normal graft function often present with hypercalcaemia, low serum phosphorus and persistently elevated levels of PTH. In eight small openlabel studies including a total of 83 patients with persistent HPT after successful kidney transplantation, cinacalcet treatment effectively corrected hypercalcaemia and significantly reduced elevated PTH levels. These studies suggest that cinacalcet therapy is an effective therapy in controlling hyperparathyroidism in patients with stage 3 and 4 CKD and in post-transplant patients with persistent
hyperparathyroidism.

Abstract

Cinacalcet has proven effective in the treatment of
secondary hyperparathyroidism (SHPT) in dialysis
patients, and it may also have benefits in stage 3 and 4
chronic kidney disease (CKD). The efficacy of cinacalcet
in the treatment of SHPT was investigated in a study of
54 patients with stage 3 and 4 CKD not receiving dialysis.
A significant number of these patients achieved at least a
30% reduction in parathyroid hormone (PTH) from baseline
with cinacalcet therapy compared with placebo (56%
versus 19%; P=0.006).Another potential use of cinacalcet
is in the treatment of persistent hyperparathyroidism (HPT)
after kidney transplantation. The pathophysiologic considerations for persistent HPT in patients who have undergone renal transplantation are different from those in stage 3 and 4 CKD. Post-transplant patients with normal graft function often present with hypercalcaemia, low serum phosphorus and persistently elevated levels of PTH. In eight small openlabel studies including a total of 83 patients with persistent HPT after successful kidney transplantation, cinacalcet treatment effectively corrected hypercalcaemia and significantly reduced elevated PTH levels. These studies suggest that cinacalcet therapy is an effective therapy in controlling hyperparathyroidism in patients with stage 3 and 4 CKD and in post-transplant patients with persistent
hyperparathyroidism.

Statistics

Citations

Altmetrics

Downloads

2 downloads since deposited on 06 Jan 2009
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Nephrology
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:chronic kidney disease • persistent hyperparathyroidism • renal transplant
Language:English
Date:2008
Deposited On:06 Jan 2009 09:10
Last Modified:05 Apr 2016 12:45
Publisher:Oxford University Press
ISSN:1753-0784
Publisher DOI:https://doi.org/10.1093/ndtplus/sfm043

Download